Companies › Yaqrit
2 active drug programs in 18 registered trials: 10 Phase 2, 3 Phase 4, 3 Phase 1, 2 Phase 3; Gastroenterology, Genitourinary, Hematology, Infectious disease; next expected readout Aug 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Filgrastim Granulocyte colony stimulating factor receptor agonist | CSF3R | Phase 2 | Acute-On-Chronic Liver Failure; Early-stage Breast Cancer; Diminished Ovarian Reserve; Allogeneic Granulocyte Donation … | Aug 2028 |
| Resatorvid (TAK-242) Toll-like receptor 4 inhibitor | TLR4 | Phase 2 | Acute-On-Chronic Liver Failure | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06520163 | Filgrastim | Phase 3 | Non-Hodgkin's Lymphoma | Oncology | Aug 2026 |
| NCT05753618 | Filgrastim | Phase 4 | Early-stage Breast Cancer | Oncology | Oct 2026 |
| NCT02143830 | Filgrastim | Phase 2 | Fanconi Anemia | Hematology | Dec 2026 |
| NCT06649851 | Filgrastim | Phase 2 | MGMT-Methylated Glioblastoma | Oncology | Jan 2027 |
| NCT07651475 | Filgrastim | Phase 2 | R/R AML | Oncology | Mar 2027 |
| NCT07012044 | Filgrastim | Phase 1 | Acute Myeloid Leukemia Post Cytotoxic Therapy | Oncology | Mar 2027 |
| NCT04262843 | Filgrastim | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | May 2027 |
| NCT06414889 | Filgrastim | Phase 1 | RUNX1 Familial Platelet Disorder | Hematology | Jun 2027 |
| NCT06742463 | Filgrastim | Phase 2 | Acute T Lymphpblastic Leukemia/Lymphoma | Oncology | Jun 2028 |
| NCT06890039 | Resatorvid (TAK-242) | Phase 2 | Acute-On-Chronic Liver Failure | Gastroenterology | Aug 2028 |
| NCT06890039 | Filgrastim | Phase 2 | Acute-On-Chronic Liver Failure | Gastroenterology | Aug 2028 |
| NCT07585136 | Filgrastim | Phase 1 | Bone Marrow Failure Syndrome | Hematology | Dec 2028 |
| NCT01624805 | Filgrastim | Phase 2 | Aplastic Anemia | Hematology | Jun 2029 |
| NCT05796570 | Filgrastim | Phase 2 | Acute Myeloid Leukemia | Oncology | Sep 2029 |
| NCT00785525 | Filgrastim | Phase 3 | Healthy | Other | Jan 2030 |
| NCT07871825 | Filgrastim | Phase 4 | Diminished Ovarian Reserve | Genitourinary | Feb 2030 |
| NCT02015013 | Filgrastim | Phase 2 | Idiopathic CD4-Positive | Infectious disease | Oct 2030 |
| NCT01553214 | Filgrastim | Phase 4 | Allogeneic Granulocyte Donation | Infectious disease | Jan 2032 |
Nanjing King-Friend Biochemical Pharmaceutical CSL Behring Savara Spectrum Pharmaceuticals Qilu Pharmaceutical Kexing Biopharm
Nefro Avillion Clinical Development LG Chem TLC Biopharmaceuticals GrandPharma (China) Brii Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.